[PDF] Next Generation Antidepressants eBook

Author : Chad E. Beyer
Publisher : Cambridge University Press
Page : 151 pages
File Size : 18,15 MB
Release : 2010-05-20
Category : Medical
ISBN : 1139833030

GET BOOK

The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.

Author : Andre F. Carvalho
Publisher : Bentham Science Publishers
Page : 416 pages
File Size : 46,72 MB
Release : 2017-07-10
Category : Medical
ISBN : 1681084732

GET BOOK

Major depressive disorder (MDD) is a prevalent, chronic, and recurring mental disorder. This disorder is a leading source of disability worldwide, and is associated with excess mortality rates. Currently approved antidepressants primarily enhance, or otherwise modulate monoaminergic neurotransmission, without curing the disease. Evidence indicates that only one third of patients with MDD achieve remission after treatment with a first-line antidepressant agent. Research in the past two decades has provided valuable insights into the pathophysiological understanding of MDD. However, there is an acknowledged ‘translational gap’ in the field, and few genuinely novel antidepressants have been approved for the treatment of MDD. The Search for Anti Depressants provides readers an in-depth picture of the main pathophysiological mechanisms responsible for the development of MDD in patients. Chapters in the volume focus on possible strategies to spur the discovery of novel antidepressants. This book is an indispensable reference for mental health care providers, students at both under-graduate and graduate levels, and neuroscientists interested in the neurobiology of MDD and recent advances towards the discovery of next generation antidepressants.

Author : Chad E. Beyer
Publisher : Cambridge University Press
Page : 151 pages
File Size : 12,51 MB
Release : 2010-05-20
Category : Medical
ISBN : 0521760585

GET BOOK

The future of mood-disorder research: covering identification of new therapeutic targets, preclinical models, and medicinal chemistry opportunities.

Author : Phil Skolnick
Publisher : Springer Science & Business Media
Page : 264 pages
File Size : 40,33 MB
Release : 1997-06-03
Category : Medical
ISBN : 1592594743

GET BOOK

In this book, leading-edge investigators offer effective strategies to improve current antidepressive therapies and suggest molecular, biological, and genetic approaches that will lead to the development of novel antidepressants. The contributors' critical reviews and commentaries illuminate our understanding of the mechanism(s) responsible for antidepressant action. The book's goal is to move beyond current biogenic amine-based concepts and therapies to the development of new and improved antidepressants that are more effective and have a more rapid onset than current.

Author :
Publisher : Elsevier
Page : 190 pages
File Size : 41,8 MB
Release : 2023-07-05
Category : Science
ISBN : 032395779X

GET BOOK

Progress in Brain Research, Volume 278, the latest release in this ongoing serial, highlights new advances in the field with this new volume presenting interesting chapters on Treatment Resistant Depression overview in Adult, Treatment Resistant Depression in Children and Adolescents, Treatment Resistant Depression in Elderly, Headache and Treatment Resistant Depression, Insomnia and Treatment Resistant Depression, Tinnitus and Treatment Resistant Depression, Genetics of Antidepressant Response and Treatment Resistant Depression, Neuroinflammation via Gut-Microbiota-Brain Axis in Treatment Resistant Depression, Molecular Imaging findings for Treatment Resistant Depression, and more. Additional sections cover Functional MRI markers for Treatment Resistant Depression: Insights and Current Challenges, Medication Strategies for Treatment Resistant Depression, Brain Stimulation for Treatment Resistant Depression, Electroconvulsive Therapy for Treatment Resistant Depression, Next Generation Antidepressants with Novel Mechanisms for Treatment Resistant Depression, Psychological aspects and Psychotherapy for Treatment Resistant Depression, and Psychiatric Rehabilitation for Treatment Resistant Depression. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in Progress in Brain Research serials Updated release includes the latest information on Treatment-Resistant Depression

Author :
Publisher : Academic Press
Page : 404 pages
File Size : 18,79 MB
Release : 2020-06-29
Category : Medical
ISBN : 0128201908

GET BOOK

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Author : Sanjay J. Mathew
Publisher : Springer
Page : 167 pages
File Size : 47,69 MB
Release : 2016-11-25
Category : Medical
ISBN : 3319429256

GET BOOK

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Author : Irving Kirsch
Publisher : Basic Books
Page : 242 pages
File Size : 25,66 MB
Release : 2010-01-26
Category : Psychology
ISBN : 0465021042

GET BOOK

Do antidepressants work? Of course -- everyone knows it. Like his colleagues, Irving Kirsch, a researcher and clinical psychologist, for years referred patients to psychiatrists to have their depression treated with drugs before deciding to investigate for himself just how effective the drugs actually were. Over the course of the past fifteen years, however, Kirsch's research -- a thorough analysis of decades of Food and Drug Administration data -- has demonstrated that what everyone knew about antidepressants was wrong. Instead of treating depression with drugs, we've been treating it with suggestion. The Emperor's New Drugs makes an overwhelming case that what had seemed a cornerstone of psychiatric treatment is little more than a faulty consensus. But Kirsch does more than just criticize: he offers a path society can follow so that we stop popping pills and start proper treatment for depression.

Author : Graziano Pinna
Publisher :
Page : 412 pages
File Size : 22,50 MB
Release : 2015-04-01
Category :
ISBN : 9781634820769

GET BOOK

Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.

Author : M. Schwab
Publisher : Karger Medical and Scientific Publishers
Page : 148 pages
File Size : 46,69 MB
Release : 2010-06-25
Category : Medical
ISBN : 3805594992

GET BOOK

In recent years, there have been major developments in the fields of pharmacogenetics and pharmacogenomics, with the potential to make drug treatments in psychiatric medicine more effective. However, improvements in drug efficacy and tolerability, as well as finding the optimal dosage, can only be realized if in vivo mechanisms of drug action and ADME (absorption, distribution, metabolism, excretion) processes (pharmacokinetics) of psychopharmacological agents are better understood. In this volume, current progress and perspectives in pharmacogenetic testing of drug-metabolizing enzymes, drug transporters and other drug targets involved in the response to psychotropic agents are described extensively. This provides a timely overview of what has been achieved in the area of psychiatric pharmacogenomics alongside some promising directions and perspectives for future research.Psychiatrists, general medical doctors as well as pharmacologists and clinical pharmacologists will find new insights into the development and applications of pharmacogenomics in psychiatry.